
- /
- Supported exchanges
- / US
- / EVAX.NASDAQ
Evaxion Biotech AS (EVAX NASDAQ) stock market data APIs
Evaxion Biotech AS Financial Data Overview
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Evaxion Biotech AS data using free add-ons & libraries
Get Evaxion Biotech AS Fundamental Data
Evaxion Biotech AS Fundamental data includes:
- Net Revenue: 3 293 K
- EBITDA: -13 842 750
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-26
- EPS/Forecast: -0.705
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evaxion Biotech AS News

European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
European equities traded in the US as American depositary receipts edged higher late Tuesday morning PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...


Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio
Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commencedThomas Schmidt appointed permanent Chief ...

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week
European equities traded in the US as American depositary receipts were tracking higher late Friday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...

Evaxion Adds GAS Vaccine Candidate EVX-B4 To Pipeline Using AI-Immunology Platform
(RTTNews) - Evaxion Biotech A/S (EVAX) announced the expansion of its vaccine pipeline with the addition of EVX-B4, a novel vaccine candidate targeting Group A Streptococcus or GAS. This new program ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.